EyePoint’s wAMD study fully enrolled ahead of expectations, says RBC Capital

EyePoint (EYPT) announced the second pivotal wet age-related macular degeneration LUCIA study has completed enrollment, with 400 patients fully enrolled and randomized within 7 months of trial initiation, RBC Capital tells investors in a research note. The firm, which has an Outperform rating and $28 price target on the shares, thinks this is positive for EyePoint as LUCIA enrolled five days ahead of expectations. The firm thinks the news is a positive development for EyePoint, but incrementally positive for shares.